Inqovi for AML maintenance – pro
Inqovi is a fixed-dose combination of oral decitabine and cedazuridine (ASTX727). In a series of bioequivalence studies, the fixed-dose combination led to blood levels of decitabine equivalent to those achieved with intravenous decitabine.2,3 These data supported the FDA’s decision to approve Inqovi on July 7 for the first-line treatment of MDS and CMML. It is not approved for relapsed AML.
Rashidi A, Walter RB, Tallman MS, et al. Maintenance therapy in acute myeloid leukemia: an evidence-based review of randomized trials. Blood. 2016;128:763-773.
Garcia-Manero G, Griffiths E, Steensma D, et al. Oral cedazuridine/decitabine: a phase 2, multicenter pharmacokinetic/pharmacodynamic randomized, crossover study in MDS and CMML. Blood. 2020;136:674-683.
NCCN AML 2025